Mind Medicine (MindMed) (MNMD) Financials

$7.20 -0.06 (-0.83%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$7.20 0.00 (-0.01%)

As of 05/30/2025 07:56 PM Eastern

Annual Income Statements for Mind Medicine (MindMed)

This table shows Mind Medicine (MindMed)'s income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-109	-96	-57
Consolidated Net Income / (Loss)	-109	-96	-57
Net Income / (Loss) Continuing Operations	-109	-96	-57
Total Pre-Tax Income	-109	-96	-57
Total Operating Income	-104	-94	-66
Total Gross Profit	0.00	0.00	0.00
Total Revenue	0.00	0.00	0.00
Total Cost of Revenue	0.00	0.00	0.00
Total Operating Expenses	104	94	66
Selling, General & Admin Expense	39	42	30
Research & Development Expense	65	52	36
Total Other Income / (Expense), net	-4.76	-1.87	9.54
Interest Expense	-0.26	0.92	-1.50
Interest & Investment Income	12	5.58	-
Other Income / (Expense), net	-17	-6.53	8.04
Basic Earnings per Share	($1.54)	($2.44)	($1.84)
Weighted Average Basic Shares Outstanding	70.46M	39.16M	30.86M
Diluted Earnings per Share	($1.54)	($2.44)	($1.84)
Weighted Average Diluted Shares Outstanding	70.46M	39.16M	30.86M
Weighted Average Basic & Diluted Shares Outstanding	75.37M	41.33M	38.06M

This table shows Mind Medicine (MindMed)'s income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-35	-14	-5.85	-54	-24	-18	-29	-25	-4.90	-16
Consolidated Net Income / (Loss)	-35	-14	-5.85	-54	-24	-18	-29	-25	-4.90	-16
Net Income / (Loss) Continuing Operations	-35	-14	-5.85	-54	-24	-18	-29	-25	-4.90	-16
Total Pre-Tax Income	-35	-14	-5.85	-54	-24	-18	-29	-25	-22	-16
Total Operating Income	-32	-25	-24	-22	-22	-22	-29	-21	-14	-17
Total Operating Expenses	32	25	24	22	22	22	29	21	14	17
Selling, General & Admin Expense	11	7.60	9.81	10	11	8.41	14	8.26	5.07	9.21
Research & Development Expense	22	17	15	12	12	13	15	13	8.83	7.77
Total Other Income / (Expense), net	-2.28	11	19	-32	-1.66	3.69	0.05	-3.95	9.00	0.50
Interest Expense	0.66	0.73	-2.08	0.43	0.44	0.33	0.08	0.08	-1.08	-0.36
Interest & Investment Income	3.28	3.51	3.12	1.66	1.35	1.49	1.39	1.36	-	-
Other Income / (Expense), net	-4.90	8.33	13	-33	-2.57	2.53	-1.26	-5.24	7.92	0.14
Basic Earnings per Share	($0.14)	($0.18)	($0.08)	($1.14)	($0.61)	($0.45)	($0.76)	($0.65)	($0.16)	($0.56)
Weighted Average Basic Shares Outstanding	70.46M	77.91M	71.91M	47.86M	39.16M	39.72M	38.58M	38.08M	30.86M	29.30M
Diluted Earnings per Share	$0.13	($0.27)	($0.26)	($1.14)	($0.61)	($0.45)	($0.76)	($0.65)	($0.16)	($0.56)
Weighted Average Diluted Shares Outstanding	70.46M	80.24M	75.30M	47.86M	39.16M	39.72M	38.58M	38.08M	30.86M	29.30M
Weighted Average Basic & Diluted Shares Outstanding	75.37M	73.33M	72.14M	71.87M	41.33M	40.09M	39.72M	38.60M	38.06M	37.57M

This table details how cash moves in and out of Mind Medicine (MindMed)'s business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	174	-42	8.60
Net Cash From Operating Activities	-79	-64	-50
Net Cash From Continuing Operating Activities	-79	-65	-50
Net Income / (Loss) Continuing Operations	-109	-96	-57
Consolidated Net Income / (Loss)	-109	-96	-57
Amortization Expense	1.25	3.26	3.18
Non-Cash Adjustments To Reconcile Net Income	32	22	7.26
Changes in Operating Assets and Liabilities, net	-3.34	6.28	-3.78
Net Cash From Investing Activities	0.00	0.00	0.00
Net Cash From Continuing Investing Activities	0.00	0.00	0.00
Acquisitions	0.00	0.00	0.00
Net Cash From Financing Activities	253	22	59
Net Cash From Continuing Financing Activities	253	22	59
Repayment of Debt	-0.13	-0.84	0.00
Issuance of Debt	10	15	0.00
Issuance of Common Equity	-10	7.53	60
Other Financing Activities, net	253	0.16	-0.99
Effect of Exchange Rate Changes	-0.03	0.08	-0.31
Cash Interest Paid	2.22	0.53	0.00

This table details how cash moves in and out of Mind Medicine (MindMed)'s business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-22	52	-9.20	153	-18	0.80	-13	-13	-12	49
Net Cash From Operating Activities	-25	-17	-20	-17	-21	-17	-14	-13	-13	-9.30
Net Cash From Continuing Operating Activities	-25	-17	-20	-17	-21	-17	-14	-13	-13	-9.30
Net Income / (Loss) Continuing Operations	-35	-14	-5.85	-54	-24	-18	-29	-25	-4.90	-16
Consolidated Net Income / (Loss)	-35	-14	-5.85	-54	-24	-18	-29	-25	-4.90	-16
Amortization Expense	0.73	-	-	0.53	0.89	0.79	0.79	0.79	0.79	0.79
Non-Cash Adjustments To Reconcile Net Income	8.89	-4.52	-11	38	5.90	1.64	5.02	8.95	-6.60	5.80
Changes in Operating Assets and Liabilities, net	-0.23	1.01	-3.45	-0.68	-3.80	-1.14	9.47	1.74	-2.13	0.60
Net Cash From Financing Activities	3.81	69	11	169	2.59	17	1.27	0.58	0.42	58
Net Cash From Continuing Financing Activities	3.81	69	11	169	2.59	17	1.27	0.58	0.42	58
Other Financing Activities, net	3.81	70	2.88	177	0.05	0.11	-	0.00	-0.31	-1.10
Effect of Exchange Rate Changes	0.00	-0.01	0.00	-0.02	-0.03	0.03	0.06	0.02	0.06	-0.14
Cash Interest Paid	0.68	0.67	0.44	0.43	0.43	0.10	-	0.00	-	-

This table presents Mind Medicine (MindMed)'s assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	302	125	170
Total Current Assets	282	104	146
Cash & Equivalents	274	100	142
Prepaid Expenses	7.88	4.17	3.91
Plant, Property, & Equipment, net	0.00	0.00	0.00
Total Noncurrent Assets	21	21	24
Goodwill	20	20	20
Intangible Assets	0.00	0.53	3.69
Other Noncurrent Operating Assets	0.61	0.22	0.33
Total Liabilities & Shareholders' Equity	302	125	170
Total Liabilities	61	46	19
Total Current Liabilities	39	32	18
Accounts Payable	2.01	4.14	2.11
Accrued Expenses	13	12	5.88
Other Current Liabilities	24	16	9.90
Total Noncurrent Liabilities	22	14	1.18
Long-Term Debt	22	14	0.00
Other Noncurrent Operating Liabilities	0.00	0.03	1.18
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	241	78	151
Total Preferred & Common Equity	241	78	151
Total Common Equity	241	78	151
Common Stock	640	368	345
Retained Earnings	-399	-290	-194
Accumulated Other Comprehensive Income / (Loss)	0.82	0.34	0.63

This table presents Mind Medicine (MindMed)'s assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	320	268	276	142	142	156	181
Total Current Assets	299	248	255	120	120	132	157
Cash & Equivalents	295	243	252	118	117	129	155
Prepaid Expenses	4.07	4.56	3.14	2.39	2.90	3.00	1.83
Other Current Assets	0.00	0.00	-	-	0.00	-	0.17
Plant, Property, & Equipment, net	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Noncurrent Assets	20	20	20	21	22	23	24
Goodwill	20	20	20	20	20	20	20
Intangible Assets	0.00	0.00	0.00	1.32	2.11	2.90	4.48
Other Noncurrent Operating Assets	0.49	0.53	0.14	0.23	0.27	0.30	-
Total Liabilities & Shareholders' Equity	320	268	276	142	142	156	181
Total Liabilities	58	66	79	46	36	25	27
Total Current Liabilities	33	42	65	31	35	24	26
Accounts Payable	2.15	2.94	7.60	7.69	8.58	2.32	0.82
Accrued Expenses	8.80	8.23	9.97	9.96	9.95	6.69	7.47
Other Current Liabilities	22	31	48	14	17	15	18
Total Noncurrent Liabilities	24	24	14	14	0.99	1.09	1.28
Long-Term Debt	24	24	14	14	-	-	-
Other Noncurrent Operating Liabilities	0.00	0.00	0.02	0.35	0.99	1.09	1.28
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	262	202	196	96	106	130	154
Total Preferred & Common Equity	262	202	196	96	106	130	154
Total Common Equity	262	202	196	96	106	130	154
Common Stock	626	552	540	362	354	349	342
Retained Earnings	-364	-350	-345	-266	-248	-219	-190
Accumulated Other Comprehensive Income / (Loss)	0.82	0.83	0.84	0.78	0.36	0.64	0.74

This table displays calculated financial ratios and metrics derived from Mind Medicine (MindMed)'s official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	0.00%	0.00%
EBITDA Growth	-22.76%	-76.25%	39.58%
EBIT Growth	-20.02%	-72.23%	37.88%
NOPAT Growth	-10.71%	-41.51%	29.33%
Net Income Growth	-13.52%	-68.55%	38.95%
EPS Growth	36.89%	-32.61%	45.88%
Operating Cash Flow Growth	-22.94%	-28.37%	-9.42%
Free Cash Flow Firm Growth	-40.92%	-33.46%	57.89%
Invested Capital Growth	-40.29%	-184.80%	-51.59%
Revenue Q/Q Growth	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-11.88%	-23.82%	17.72%
EBIT Q/Q Growth	-11.67%	-23.02%	16.91%
NOPAT Q/Q Growth	-10.95%	-9.71%	5.23%
Net Income Q/Q Growth	-11.12%	-24.70%	17.35%
EPS Q/Q Growth	-22.22%	-26.42%	21.70%
Operating Cash Flow Q/Q Growth	-6.44%	-13.62%	-11.12%
Free Cash Flow Firm Q/Q Growth	-8.24%	6.92%	0.00%
Invested Capital Q/Q Growth	-18.90%	2.76%	1,047.62%
Profitability Metrics	-	-	-
Gross Margin	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%
Interest Burden Percent	90.19%	95.35%	97.44%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%
Return on Equity (ROE)	-68.01%	-83.59%	-37.54%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-275.70%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-68.01%	-83.59%	-37.54%
Return on Equity Simple (ROE_SIMPLE)	-45.01%	-122.52%	-37.63%
Net Operating Profit after Tax (NOPAT)	-73	-66	-46
NOPAT Margin	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-21.30%	-26.37%	-7.52%
Return On Investment Capital (ROIC_SIMPLE)	-27.63%	-71.22%	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-120	-100	-58
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-119	-97	-55
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	2.11	1.88	0.55
Price to Tangible Book Value (P/TBV)	2.30	2.54	0.65
Price to Revenue (P/Rev)	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.09	0.18	0.00
Long-Term Debt to Equity	0.09	0.18	0.00
Financial Leverage	-1.06	-0.99	-0.91
Leverage Ratio	1.34	1.29	1.10
Compound Leverage Factor	1.20	1.23	1.08
Debt to Total Capital	8.30%	15.31%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	8.30%	15.31%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.70%	84.69%	100.00%
Debt to EBITDA	-0.18	-0.15	0.00
Net Debt to EBITDA	2.11	0.88	0.00
Long-Term Debt to EBITDA	-0.18	-0.15	0.00
Debt to NOPAT	-0.30	-0.22	0.00
Net Debt to NOPAT	3.46	1.30	0.00
Long-Term Debt to NOPAT	-0.30	-0.22	0.00
Altman Z-Score	2.84	-3.34	0.77
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	7.25	3.22	8.16
Quick Ratio	7.05	3.09	7.94
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-70	-49	-37
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-53.79	0.00
Operating Cash Flow to Interest Expense	0.00	-69.96	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	-69.96	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-
Invested Capital	-10	-7.44	8.78
Invested Capital Turnover	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-3.00	-16	-9.35
Enterprise Value (EV)	259	61	-59
Market Capitalization	510	147	83
Book Value per Share	$3.29	$1.95	$4.02
Tangible Book Value per Share	$3.02	$1.44	$3.39
Total Capital	263	92	151
Total Debt	22	14	0.00
Total Long-Term Debt	22	14	0.00
Net Debt	-252	-86	-142
Capital Expenditures (CapEx)	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-31	-28	-14
Debt-free Net Working Capital (DFNWC)	243	72	128
Net Working Capital (NWC)	243	72	128
Net Nonoperating Expense (NNE)	36	30	10
Net Nonoperating Obligations (NNO)	-252	-86	-142
Total Depreciation and Amortization (D&A)	1.25	3.26	3.18
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.54)	($2.44)	($1.84)
Adjusted Weighted Average Basic Shares Outstanding	70.46M	39.16M	30.86M
Adjusted Diluted Earnings per Share	($1.54)	($2.44)	($1.84)
Adjusted Weighted Average Diluted Shares Outstanding	70.46M	39.16M	30.86M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	75.37M	41.33M	38.06M
Normalized Net Operating Profit after Tax (NOPAT)	-73	-66	-46
Normalized NOPAT Margin	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	-109.13	0.00
NOPAT to Interest Expense	0.00	-71.42	0.00
EBIT Less CapEx to Interest Expense	0.00	-109.13	0.00
NOPAT Less CapEx to Interest Expense	0.00	-71.42	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Mind Medicine (MindMed)'s official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-53.44%	10.01%	62.75%	-117.70%	-359.83%	-13.95%	-82.82%	-43.44%	69.56%	1.76%
EBIT Growth	-50.84%	13.74%	63.72%	-113.12%	-314.01%	-13.30%	-78.65%	-41.66%	66.48%	1.68%
NOPAT Growth	-46.20%	-14.69%	16.19%	-6.43%	-59.74%	-27.28%	-72.25%	-12.74%	20.84%	1.42%
Net Income Growth	-45.58%	23.65%	79.90%	-119.22%	-386.72%	-8.72%	-71.79%	-34.49%	70.87%	4.13%
EPS Growth	121.31%	40.00%	65.79%	-75.38%	-281.25%	19.64%	-26.67%	1.52%	73.77%	8.20%
Operating Cash Flow Growth	-23.28%	-3.40%	-44.38%	-24.51%	-60.04%	-78.83%	8.47%	-3.61%	-64.04%	44.60%
Free Cash Flow Firm Growth	-3,030.10%	-93.05%	-221.09%	3,357.74%	277.16%	23.32%	130.23%	102.71%	0.00%	0.00%
Invested Capital Growth	-40.29%	-14.74%	-54.12%	-4,600.86%	-184.80%	-726.35%	-158.22%	-94.28%	-51.59%	0.00%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	-122.54%	-49.06%	79.95%	-129.75%	-30.52%	38.30%	-17.16%	-387.35%	67.65%	1.01%
EBIT Q/Q Growth	-126.94%	-49.06%	80.14%	-124.55%	-29.78%	37.30%	-16.64%	-336.22%	64.48%	1.14%
NOPAT Q/Q Growth	-30.94%	-1.37%	-10.15%	0.00%	-2.72%	25.93%	-39.89%	-50.09%	18.15%	-0.24%
Net Income Q/Q Growth	-153.88%	-133.75%	89.24%	-127.96%	-33.15%	38.47%	-17.39%	-406.12%	70.26%	2.78%
EPS Q/Q Growth	148.15%	-3.85%	77.19%	-86.89%	-35.56%	40.79%	-16.92%	-306.25%	71.43%	6.67%
Operating Cash Flow Q/Q Growth	-47.47%	14.00%	-20.43%	19.28%	-23.68%	-20.09%	-3.86%	-3.75%	-38.21%	38.54%
Free Cash Flow Firm Q/Q Growth	-21.56%	-44.75%	-140.80%	3,981.28%	108.01%	-190.80%	1,065.01%	309.11%	96.53%	64.20%
Invested Capital Q/Q Growth	-18.90%	47.84%	60.00%	-465.56%	2.76%	29.95%	-1,268.24%	-89.34%	1,047.62%	-104.94%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	22.43%	100.00%
Interest Burden Percent	92.98%	83.11%	53.00%	97.80%	96.34%	93.91%	95.69%	95.08%	365.37%	97.86%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-68.01%	-54.61%	-66.26%	-76.79%	-83.59%	-61.52%	-65.37%	-47.28%	-37.54%	-44.74%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-378.55%	-275.70%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-68.01%	-54.61%	-66.26%	-76.79%	-83.59%	-61.52%	-65.37%	-47.28%	-37.54%	-44.74%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-37.30%	-50.50%	-63.92%	0.00%	-79.99%	-71.09%	-48.46%	0.00%	-44.74%
Net Operating Profit after Tax (NOPAT)	-23	-17	-17	-16	-16	-15	-20	-15	-9.73	-12
NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-7.12%	1.96%	6.71%	-21.14%	-7.31%	-2.16%	-7.82%	-8.17%	3.50%	-5.95%
Return On Investment Capital (ROIC_SIMPLE)	-8.63%	-	-	-	-16.85%	-	-	-	-	-
Cost of Revenue to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-37	-16	-11	-56	-25	-19	-30	-26	-5.98	-17
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-37	-16	-11	-55	-24	-18	-30	-25	-5.19	-16
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	2.11	1.57	2.56	1.92	1.88	1.30	1.30	0.93	0.55	0.65
Price to Tangible Book Value (P/TBV)	2.30	1.69	2.85	2.14	2.54	1.66	1.64	1.12	0.65	0.77
Price to Revenue (P/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.09	0.09	0.12	0.07	0.18	0.15	0.00	0.00	0.00	0.00
Long-Term Debt to Equity	0.09	0.09	0.12	0.07	0.18	0.15	0.00	0.00	0.00	0.00
Financial Leverage	-1.06	-1.05	-1.09	-1.13	-0.99	-1.03	-0.97	-0.94	-0.91	-1.01
Leverage Ratio	1.34	1.29	1.33	1.32	1.29	1.29	1.20	1.14	1.10	1.18
Compound Leverage Factor	1.24	1.07	0.71	1.29	1.24	1.21	1.15	1.08	4.03	1.15
Debt to Total Capital	8.30%	8.49%	10.72%	6.75%	15.31%	12.78%	0.00%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	8.30%	8.49%	10.72%	6.75%	15.31%	12.78%	0.00%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	91.70%	91.51%	89.28%	93.25%	84.69%	87.22%	100.00%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.18	-0.23	-0.22	-0.11	-0.15	-0.18	0.00	0.00	0.00	0.00
Net Debt to EBITDA	2.11	2.54	2.02	1.87	0.88	1.32	0.00	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.18	-0.23	-0.22	-0.11	-0.15	-0.18	0.00	0.00	0.00	0.00
Debt to NOPAT	-0.30	-0.37	-0.38	-0.21	-0.22	-0.23	0.00	0.00	0.00	0.00
Net Debt to NOPAT	3.46	4.13	3.46	3.57	1.30	1.73	0.00	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.30	-0.37	-0.38	-0.21	-0.22	-0.23	0.00	0.00	0.00	0.00
Altman Z-Score	3.75	3.51	3.66	1.26	-1.33	-0.69	-0.15	1.18	1.79	1.28
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	7.25	9.00	5.92	3.91	3.22	3.85	3.41	5.50	8.16	6.01
Quick Ratio	7.05	8.88	5.81	3.87	3.09	3.78	3.33	5.37	7.94	5.93
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-20	-16	-11	27	0.67	-8.41	9.26	0.79	-0.38	-11
Operating Cash Flow to CapEx	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	-30.07	-22.32	0.00	63.31	1.53	-25.63	120.22	10.46	0.00	0.00
Operating Cash Flow to Interest Expense	-38.64	-23.65	0.00	-38.24	-46.84	-50.69	-179.81	-175.41	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-38.64	-23.65	0.00	-38.24	-46.84	-50.69	-179.81	-175.41	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-10	-8.78	-17	-42	-7.44	-7.65	-11	0.94	8.78	-0.93
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-3.00	-1.13	-5.91	-43	-16	-6.73	-30	-15	-9.35	-0.93
Enterprise Value (EV)	259	140	299	139	61	21	21	-8.75	-59	-55
Market Capitalization	510	411	518	377	147	124	138	121	83	100
Book Value per Share	$3.29	$3.63	$2.81	$4.10	$1.95	$2.42	$2.75	$3.42	$4.02	$0.36
Tangible Book Value per Share	$3.02	$3.36	$2.53	$3.68	$1.44	$1.88	$2.18	$2.83	$3.39	$0.30
Total Capital	263	287	226	210	92	110	106	130	151	154
Total Debt	22	24	24	14	14	14	0.00	0.00	0.00	0.00
Total Long-Term Debt	22	24	24	14	14	14	0.00	0.00	0.00	0.00
Net Debt	-252	-271	-219	-238	-86	-104	-117	-129	-142	-155
Capital Expenditures (CapEx)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-31	-29	-37	-62	-28	-29	-32	-21	-14	-24
Debt-free Net Working Capital (DFNWC)	243	266	206	190	72	89	85	108	128	130
Net Working Capital (NWC)	243	266	206	190	72	89	85	108	128	130
Net Nonoperating Expense (NNE)	12	-3.67	-11	39	8.32	2.79	8.70	10	-4.83	4.60
Net Nonoperating Obligations (NNO)	-252	-271	-219	-238	-86	-104	-117	-129	-142	-155
Total Depreciation and Amortization (D&A)	0.73	0.00	0.00	0.53	0.89	0.79	0.79	0.79	0.79	0.79
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.14)	($0.18)	($0.08)	($1.14)	($0.61)	($0.45)	($0.76)	($0.65)	($0.16)	($0.56)
Adjusted Weighted Average Basic Shares Outstanding	70.46M	77.91M	71.91M	47.86M	39.16M	39.72M	38.58M	38.08M	30.86M	29.30M
Adjusted Diluted Earnings per Share	$0.13	($0.27)	($0.26)	($1.14)	($0.61)	($0.45)	($0.76)	($0.65)	($0.16)	($0.56)
Adjusted Weighted Average Diluted Shares Outstanding	70.46M	80.24M	75.30M	47.86M	39.16M	39.72M	38.58M	38.08M	30.86M	29.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	($0.61)	$0.00	$0.00	$0.00	($0.16)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	75.37M	73.33M	72.14M	71.87M	41.33M	40.09M	39.72M	38.60M	38.06M	37.57M
Normalized Net Operating Profit after Tax (NOPAT)	-23	-17	-17	-16	-16	-15	-20	-15	-9.73	-12
Normalized NOPAT Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-56.96	-22.65	0.00	-128.16	-56.42	-58.19	-395.34	-343.41	0.00	0.00
NOPAT to Interest Expense	-34.64	-23.87	0.00	-35.81	-35.41	-46.13	-265.31	-192.15	0.00	0.00
EBIT Less CapEx to Interest Expense	-56.96	-22.65	0.00	-128.16	-56.42	-58.19	-395.34	-343.41	0.00	0.00
NOPAT Less CapEx to Interest Expense	-34.64	-23.87	0.00	-35.81	-35.41	-46.13	-265.31	-192.15	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Mind Medicine (MindMed)'s Financials

When does Mind Medicine (MindMed)'s fiscal year end?

According to the most recent income statement we have on file, Mind Medicine (MindMed)'s financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Mind Medicine (MindMed)'s net income changed over the last 2 years?

Mind Medicine (MindMed)'s net income appears to be on an upward trend, with a most recent value of -$108.68 million in 2024, rising from -$56.80 million in 2022. The previous period was -$95.73 million in 2023. See Mind Medicine (MindMed)'s forecast for analyst expectations on what’s next for the company.

What is Mind Medicine (MindMed)'s operating income?

Mind Medicine (MindMed)'s total operating income in 2024 was -$103.92 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $103.92 million

How has Mind Medicine (MindMed) revenue changed over the last 2 years?

Over the last 2 years, Mind Medicine (MindMed)'s total revenue changed from $0.00 in 2022 to $0.00 in 2024, a change of 0.0%.

How much debt does Mind Medicine (MindMed) have?

Mind Medicine (MindMed)'s total liabilities were at $60.70 million at the end of 2024, a 30.8% increase from 2023, and a 218.2% increase since 2022.

How much cash does Mind Medicine (MindMed) have?

In the past 2 years, Mind Medicine (MindMed)'s cash and equivalents has ranged from $99.70 million in 2023 to $273.74 million in 2024, and is currently $273.74 million as of their latest financial filing in 2024.

How has Mind Medicine (MindMed)'s book value per share changed over the last 2 years?

Over the last 2 years, Mind Medicine (MindMed)'s book value per share changed from 4.02 in 2022 to 3.29 in 2024, a change of -18.0%.

Related Companies

This page (NASDAQ:MNMD) was last updated on 6/1/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mind Medicine (MindMed) (MNMD) Financials

Frequently Asked Questions About Mind Medicine (MindMed)'s Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mind Medicine (MindMed) (MNMD) Financials

Annual Income Statements for Mind Medicine (MindMed)

Quarterly Income Statements for Mind Medicine (MindMed)

Annual Cash Flow Statements for Mind Medicine (MindMed)

Quarterly Cash Flow Statements for Mind Medicine (MindMed)

Annual Balance Sheets for Mind Medicine (MindMed)

Quarterly Balance Sheets for Mind Medicine (MindMed)

Annual Metrics And Ratios for Mind Medicine (MindMed)

Quarterly Metrics And Ratios for Mind Medicine (MindMed)

Frequently Asked Questions About Mind Medicine (MindMed)'s Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools